Harnessing these beneficial probiotic properties, we set out to develop L. lactis as a carrier of the anti-IL-6 affibody that will be able to decrease the content of free IL-6 in the intestine and thus block its detrimental effects in IBD. The gene discussed is IL6; the disease is inflammatory bowel disease.